Solution structure of iron(III)-anthracycline complexes

被引:26
作者
Fiallo, MML
Drechsel, H
Garnier-Suillerot, A
Matzanke, BF
Kozlowski, H
机构
[1] Univ Paris 13, LPBC, ESA 7033, F-93017 Bobigny, France
[2] Univ Lubeck, Isotope Lab Nat Sci, D-2400 Lubeck, Germany
[3] Univ Wroclaw, Fac Chem, PL-50138 Wroclaw, Poland
关键词
D O I
10.1021/jm981057n
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The interaction of Fe3+ with the anthracycline anticancer drug idarubicin (Ida) was studied by absorption, CD, Mossbauer, and EPR spectroscopy. The formation of two major Fe3+-Ida complexes, labeled I and II, was observed. In complex I, Fe3+ ion was bound to anthracycline at the {C(12)=O; C(11)-O-} coordination site. In complex II, two Fe3+ ions were bound at sites {C(5)=O; C(6)-O-} and {C(12)=O; C(11)-O-}, respectively. Complex I was an equimolar monomeric species with a 1:1 Fe3+:Ida stoichiometry (beta(1) = 4.8 x 10(11) M-1), whereas in complex II the anthracycline ligand was bridging two metal ions, alternatively bound to both anthracycline ring chelating sites with the assumption that the ratio of Fe3+:Ida in complex II was 2:1 (beta(2) = 5.3 x 10(24) M-2). Alternatively, complex II may be oligomeric with Fe3+:Ida = 1:1 and with each Fe3+ bridging two Ida molecules. Our findings could be important in understanding the biological effects of the anthracycline-ferric complexes. Thus, providing information about the nature of the Fe3+-Ida system, we suggest that the formal 1:3 Fe3+:anthrracycline complexes, reported in the previous literature, could be a mixture of species I, II, and free ligand.
引用
收藏
页码:2844 / 2851
页数:8
相关论文
共 43 条
[21]  
GELVAN D, 1988, CANCER RES, V48, P5645
[22]   TIME-DEPENDENT MODIFICATIONS OF FERRIC ADRIAMYCIN [J].
GELVAN, D ;
BERG, E ;
SALTMAN, P ;
SAMUNI, A .
BIOCHEMICAL PHARMACOLOGY, 1990, 39 (08) :1289-1295
[23]   Probing the chloroquine resistance locus of Plasmodium falciparum with a novel class of multidentate metal(III) coordination complexes [J].
Goldberg, DE ;
Sharma, V ;
Oksman, A ;
Gluzman, IY ;
Wellems, TE ;
PiwnicaWorms, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (10) :6567-6572
[24]   QUELAMYCIN, A NEW DERIVATIVE OF ADRIAMYCIN WITH SEVERAL POSSIBLE THERAPEUTIC ADVANTAGES [J].
GOSALVEZ, M ;
BLANCO, MF ;
VIVERO, C ;
VALLES, F .
EUROPEAN JOURNAL OF CANCER, 1978, 14 (11) :1185-1190
[25]   BIOCHEMISTRY OF MULTIDRUG-RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTER [J].
GOTTESMAN, MM ;
PASTAN, I .
ANNUAL REVIEW OF BIOCHEMISTRY, 1993, 62 :385-427
[26]  
HAJ HT, 1994, DALTON T, P3689
[27]   Decreased sensitivity to adriamycin in cadmium-resistant human lung carcinoma A549 cells [J].
Hatcher, EL ;
Alexander, JM ;
Kang, YJ .
BIOCHEMICAL PHARMACOLOGY, 1997, 53 (05) :747-754
[28]   TRANSPORT OF AN IRON - ANTHRACYCLINE COMPLEX BY MURINE LEUKEMIA-CELLS [J].
KESSEL, D .
CANCER LETTERS, 1988, 42 (03) :213-218
[29]   INTERPRETING THE VISIBLE ABSORPTION-BANDS OF 1,4-(DIHYDROXY)-9,10-ANTHRAQUINONE AND ITS METAL-CHELATES [J].
KOCH, TS ;
RAVA, RP .
BIOPHYSICAL CHEMISTRY, 1990, 36 (03) :187-199
[30]  
LYNCH JB, 1989, J BIOL CHEM, V264, P8091